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Abstract
A workshop on pediatric preclinical testing, sponsored
by the National Cancer Institute and the Children’s Oncol-
ogy Group Phase 1 Consortium, was held on June 26–27,
2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter
Houghton, and Malcolm Smith organized and hosted the
meeting. There were 20 participants from 12 institutions.
The primary objectives of the workshop included: (a) devel-
opment of a working inventory of available preclinical mod-
els (including human tumor xenografts in immunodeficient
mice, transgenic and syngeneic tumors, and selected in vitro
models), with a basic understanding of the strengths and
weaknesses of each as possible components of a preclinical
testing program; (b) identification of the key scientific issues
related to establishment of a program for preclinical testing
of new agents for their applicability to childhood cancers;
and (c) identification of the key infrastructure requirements
for a program for preclinical testing of new agents for their
applicability to childhood cancers. This report is a synthesis
of the workshop’s presentations and discussions.
Introduction
Approximately 400 new agents are currently under evalu-
ation for cancer indications in adults (1). Only a small fraction
of these can be evaluated in children with cancer as a result of
the thankfully small number of children eligible for clinical
trials evaluating new agents and the inherent limitations this
places on the number of pediatric clinical trials that can be
conducted. Because of this increasing imbalance between the
number of new agents potentially available for pediatric evalu-
ation and the number that can actually be evaluated, it is
essential to develop predictive preclinical models of pediatric
cancers to help clinical investigators prioritize new anticancer
agents for testing in children.
Preclinical testing of anticancer agents using pediatric cell
lines and in vivo model systems has occurred for more than two
decades. However, pediatric preclinical testing has never been
consistently supported, and neither pharmaceutical companies
nor the NCI
2 has included pediatric models as standard compo-
nents of preclinical testing programs. Consequently, a substan-
tial proportion of pediatric Phase I trials have been conducted
with limited or no prior testing of the agents in pediatric pre-
clinical models.
There are, however, a select number of pediatric preclinical
tumor models that appear to be predictive for future clinical
activity. The best studied tumor has been rhabdomyosarcoma.
Retrospective studies have demonstrated a strong correlation
between the activity of agents against rhabdomyosarcoma xe-
nografts and clinical activity of the same agents (2). Melphalan
was first identified as an active agent against rhabdomyosar-
coma in xenograft models, and subsequent clinical experience
with melphalan in children with newly diagnosed rhabdomyo-
sarcoma mirrored the activity observed in the xenograft models
(3). The prospective identification of topoisomerase I inhibitors
as active agents against rhabdomyosarcoma xenograft models
(4) and the subsequent demonstration of antitumor activity for
these agents in children with rhabdomyosarcoma further support
the predictive ability of these xenograft models (5).
Xenograft models of neuroblastoma, similar to rhabdomy-
osarcoma, also have predicted for the future clinical activity of
Received 3/5/02; revised 7/9/02; accepted 7/30/02.
1 To whom requests for reprints should be addressed, at Pediatric
Section, Cancer Therapy Evaluation Program, National Cancer Institute,
6130 Executive Boulevard, Room 7025, Bethesda, MD 20892-7436.
Phone: (301) 496-2522; Fax: (301) 402-0557; E-mail: smithm@
ctep.nci.nih.gov.
2 The abbreviations used are: NCI, National Cancer Institute; JMML,
juvenile myelomonocytic leukemia; ALL, acute lymphoblastic leuke-
mia; PNET, primitive neuroectodermal tumor; MTD, maximum toler-
ated dose.
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that neuroblastoma cell lines established at different points of
therapy acquire a sustained drug-resistant phenotype that mir-
rors the clinical resistance pattern of patients supports the clin-
ical relevance of the drug sensitivity pattern of these neuroblas-
toma cell lines (7).
Despite these and other examples of correlations between
drug activity in pediatric preclinical models and clinical activity
against tumors in children, the absence of a coordinated and
consistent approach to the preclinical evaluation of new agents
has prevented a definitive determination of the role of preclin-
ical testing in prioritizing new agents for evaluation in children
with cancer. Because of this lack of a systematic approach to
preclinical testing, questions remain about the validity of pre-
clinical models as predictors of clinical benefit in children with
cancer.
As an initial step in developing a systematic approach to
the prioritization of new agents for pediatric evaluation, the
Children’s Oncology Group Phase 1 Consortium and the Cancer
Therapy Evaluation Program (NCI) sponsored a meeting on
June 26–27, 2001 in Rockville, Maryland of investigators who
have studied preclinical models potentially applicable to child-
hood cancer. Meeting participants were asked to address the
following objectives: (a) development of a working inventory of
available preclinical models, including a summary of the poten-
tial strengths and weaknesses of currently available models; (b)
identification of the key scientific issues related to establishment
of a program for preclinical testing of new agents for their
applicability to childhood cancers; and (c) identification of the
key infrastructure requirements for a program for preclinical
testing of new agents for their applicability to childhood
cancers.
Data presented at the meeting documented the existence of
potential models (either xenograft, transgenic, or in vitro) for a
number of childhood cancers, including rhabdomyosarcoma,
osteosarcoma, Ewing’s sarcoma/peripheral PNET, neuroblas-
toma, various types of brain cancers, JMML, and ALL. The
meeting summary that follows focuses primarily on the scien-
tific issues related to the establishment and design of a system
for analytically testing new anticancer agents in pediatric pre-
clinical models and on issues related to the infrastructure re-
quirements of such a system. Also included is a brief summary
of existing preclinical models.
Existing Pediatric Tumor Models
In Vitro Model Systems. In vitro model systems have
been widely used to test the activity of anticancer agents against
childhood cancer primary cells and cell lines, and such models
continue to be used as a component of the NCI cell line screen
for adult tumors (8, 9). Most in vitro model systems use either
a clonogenic survival end point, measured by colony formation,
or a cell proliferation end point, measured by cell metabo-
lism [e.g., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazo-
lium-5-carboxanilide inner salt] or biomass (e.g., SRB) assays
(10). One proliferative end point assay presented at the meeting
utilizes a fluorescence-based system (DIMSCAN), which has a
wide dynamic range (3–4 logs of cell kill) with moderately high
throughput. DIMSCAN has been used to study neuroblastoma
cell lines established from tumors at various stages of treatment
[diagnosis, postinduction, and post bone marrow transplantation
(7, 11, 12)]. The DIMSCAN assay and other in vitro assays are
particularly well suited for defining synergistic interactions be-
tween drugs (13, 14). Whereas in vitro testing has generally
shown limited success in predicting tumor-specific clinical ac-
tivity in studies of adult tumors, it remains an open question
whether testing against a broad panel of carefully selected and
well-characterized childhood cancer cell lines can provide clin-
ically useful information.
Primary tumor cells have also been used for in vitro drug
testing. For example, primary blast cells from children with
ALL have been used to test the antileukemia activity of agents
and to correlate in vitro sensitivity to molecularly targeted
agents with molecular alterations in the leukemia cells (15, 16).
In Vivo Model Systems. Most pediatric preclinical in
vivo testing has involved tumor xenografts, for which several
host animal options exist, including SCID mice, NOD/SCID
mice, athymic nude mice, and athymic rats. Most recent work in
pediatric solid tumor models has used SCID mice, whereas for
leukemia models, use of NOD/SCID mice has been more com-
mon. Tables 1 and 2 list some of the pediatric xenograft models
and the anticancer drugs that have been studied in the models.
Perhaps the most influential xenograft experiments have been
those evaluating the activity of the camptothecin analogues
against pediatric tumors. These experiments demonstrated the
schedule-dependent activity of the topoisomerase I inhibitors
and their high levels of activity against neuroblastoma and
rhabdomyosarcoma xenografts at drug exposures achievable in
humans (4, 17, 18). The predicted activity of topotecan and
irinotecan against neuroblastoma and rhabdomyosarcoma has
been confirmed in clinical trials in children with these diagnoses
(5, 6, 18). Testing in pediatric xenograft models has not been
limited to conventional cytotoxic agents. For example, antian-
giogenic agents [e.g., TNP-470 (19), the v integrin antagonist
EMD-121974 (20), and an antibody to vascular endothelial
growth factor (21, 22)] and signal transduction inhibitors [e.g.,
the Trk family tyrosine kinase inhibitor CEP-751 (23) and the
epidermal growth factor receptor inhibitor ZD1839 (24)] have
all been evaluated in xenograft models. Although most work
with pediatric xenograft models has been for solid tumors,
xenograft models of childhood ALL have been developed that
have the requisite characteristics of rapid, high-level, uniform
leukemia engraftment (25, 26). These ALL xenograft models
appear to have potential utility for preclinical testing (27, 28).
Most xenograft testing of anticancer agents has been done
with tumors implanted s.c., which has a number of practical
advantages (e.g., the ease of evaluating tumor response). The
biology of pediatric tumors growing s.c. may differ from that of
tumors growing in environments that more closely mimic their
site of origin. Alternatives to s.c. models include orthotopic
xenograft models (20) and models in which i.v. injection of
tumor cells into SCID mice achieves various organ distributions
(29). Assessing response is a challenge with any of these intra-
cavitary mouse tumor models, but new capabilities for small
animal imaging may help address this challenge (30–32).
Transgenic models may make important contributions to a
pediatric preclinical testing program. At the pretesting stage,
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targets for specific tumor types. Transgenic models may be
particularly useful in evaluating targeted therapies for which the
model has been engineered to focus on the target pathway of the
agent of interest. As an example, JMML has been modeled
using Nf1 mutant mice. Approximately 10% of mice with het-
erozygous inactivation of Nf1 develop a myeloproliferative dis-
order during the second year of life (33), although the limited
penetrance precludes use of Nf1 heterozygous mice for drug
testing. However, adoptive transfer of homozygous Nf1 mutant
fetal liver hematopoietic cells to irradiated recipients consis-
tently produces a JMML-like myeloproliferative disorder (34,
35). This model of pediatric JMML has been used to evaluate
the antileukemia activity of a farnesyl transferase inhibitor,
although the process for drug testing is time- and labor-intensive
(36).
A mouse model of neuroblastoma involving overexpres-
sion of the MYCN gene has also been used for drug testing. In
this model, N-myc expression is targeted to neural crest cells by
linkage to the tyrosine hydroxylase promoter (37). Homozygous
MYCN transgenic mice develop neuroblastoma within a tight
window at 6–7 weeks of age, with amplification of the trans-
Table 1 Pediatric murine and xenograft tumor models presented at the meeting
Tumor type Investigator Classification
No. of
lines Comments
ALL R. Lock (25, 28) c-ALL 11 Xenografts produce systemic disease with infiltration
of bone marrow, spleen, and liver. Engraftment
and drug responses are measured by tail vein
bleed. 14 lines were obtained at diagnosis, 6 at
relapse (1 matched pair).
T-ALL 3
Pre-B 2
Early pre-B 1
Ph ALL 1
Biphenotypic 1
J. Yu (27) Preconditioning NOD/SCID mice with cord blood-
derived cells allows a high level of engraftment
for primary ALL and AML
a cells.
CNS: glial tumors P. Houghton Ependymoma 5
Low-grade astrocytoma 2
High-grade glioma line 2
CNS: medulloblastoma and
other embryonal tumors
P. Houghton PNET 2
Medulloblastoma 4
Atypical teratoid
rhabdoid
6
Ewing’s sarcoma/peripheral
PNET
P. Reynolds Ewing’s sarcoma/PNET 12 Most of these cell lines grow as s.c. xenografts in
athymic mice. Selected cell lines have been shown
to uniformly form pulmonary metastases
(detectable by high-resolution radiographs) when
given by i.v. injection into SCID mice.
Neuroblastoma P. Houghton 6 4/6 tumors obtained at relapse; and 5/6 were MNYC
amplified. Tumors from patients at relapse were
generally resistant to standard drugs. 97 new agent
and combination studies were completed (1998–
2001).
J. Maris MYCN amplified 1 Also presented was a metastatic model using cell
lines transfected with GFP and an orthotopic
model for adrenal tumors. 11q23 deleted 2
P. Reynolds 18 Cell lines established after various phases of therapy
show drug resistance patterns expected for the
phase of therapy. All lines have been
characterized for response in vitro to most drugs
used for neuroblastoma therapy.
Osteosarcoma R. Gorlick Primary site 4
Pulmonary recurrence 2
P. Houghton Primary site 10
Pulmonary recurrence 3
L. Helman
(51, 52)
Rodent model Rodent model of metastatic osteosarcoma was used
to identify functional and genetic differences
between highly metastatic and poorly metastatic
tumor cells.
Rhabdomyosarcoma P. Houghton Embryonal diagnosis 4 All lines express MyoD and/or myogenin, and the
alveolar lines have t(2;13) and express
Pax3/FKHR. 95 new agent and combination
studies were completed (1998–2001).
Alveolar diagnosis 2
Embryonal relapse 3
Alveolar relapse 4
Wilms’ tumor P. Houghton Favorable histology 9 The tumors are very sensitive to cyclophosphamide,
vincristine, topotecan, and irinotecan. The
anaplastic tumor is less responsive to
chemotherapy than the favorable histology tumors.
Anaplastic 1
a AML, acute myeloid leukemia; CNS, central nervous system; GFP, green fluorescent protein.
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tumor development occurring with a predictable time course
makes this model quite tractable for drug testing. MYCN trans-
genic mice respond to the conventional chemotherapy agent
cyclophosphamide, and MYCN transgenic mice treated with
MYCN antisense oligonucleotides have reduced tumor incidence
and develop smaller tumor mass than animals treated with
control oligonucleotides (39). Table 3 provides a listing of some
of the genetically engineered murine models for pediatric tu-
mors that have been developed.
Core Model Requirements
The primary goal of a preclinical testing program is to
improve outcome for children with cancer by the early identi-
fication of potential pediatric applications for new agents in
clinical development. The premise for establishing a testing
program is that its activities will allow agents (or combinations
of agents) to be selected for clinical evaluation that have in-
creased likelihood for clinical benefit. In the absence of an
effective preclinical testing program, a preponderance of inef-
fective agents will be selected for evaluation, thus slowing
progress in improving outcome. This hypothesis, although not
testable in a randomized manner, requires validation. A pediat-
ric preclinical testing program, although based on scientific
principles and designed to pursue scientific opportunities as they
arise, would have the very pragmatic objective of providing
reliable information to clinical investigators to allow an enlight-
ened prioritization among the multiple agents available for
clinical evaluation in children.
A leading issue in the design of a preclinical testing pro-
gram is the selection of tumor models to study. The first deter-
mination will be the tumor types to be studied, because it will
likely not be possible to study every type of childhood cancer
initially. Factors influencing the selection of tumor types for
study include tumor incidence, the adequacy of current therapy
for the tumor (i.e., the need for new treatment strategies),
overlap with adult tumor types (i.e., can data from adult pre-
clinical testing be applied to the pediatric setting), the availabil-
Table 2 Preclinical testing of new agents in pediatric tumor models
Tumor type
Examples of published reports of anticancer agents studied in
pediatric xenograft models
ALL B43 (anti-CD19)-pokeweed antiviral protein immunotoxin (53, 54)
TXU (anti-CD7)-pokeweed antiviral protein immunotoxin (55)
Vincristine (25, 28)
CNS:
a glial tumors EMD-121974 (20)
Irinotecan (56)
Temozolomide (57, 58)
ZD1839 (24)
CNS: medulloblastoma and
other embryonal tumors
Busulfan (59, 60)
CEP 751 (23)
Ecteinascidin-743 (61)
EMD-121974 (20)
Irinotecan (62)
Temozolomide (57, 58)
Neuroblastoma 9-Aminocamptothecin (45)
Busulfan (60)
CEP-751 (23)
Ecteinascidin-743 (61)
Human IgM (63)
Irinotecan (64, 65)
MGI 114 (66)
Temozolomide (58)
TNP-470 (19)
Topotecan (29, 67)
Vincristine (29, 67)
ZD1839 (24)
Osteosarcoma Antiosteosarcoma immunotoxin (68, 69)
Topotecan (70)
Rhabdomyosarcoma 9-Aminocamptothecin (45)
Irinotecan (71)
Melphalan (3)
MGI 114 (66)
Rapamycin (47)
Temozolomide (58)
Topotecan (67)
Vincristine (67)
ZD1839 (24)
Wilms’ tumor Antibody to vascular endothelial growth factor as either a single
agent (22) or in combination with low-dose chemotherapy (21)
a CNS, central nervous system.
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ties related to evaluation of targeted therapies that require study
in tumor models for which the target is relevant. If selection of
tumor types was based on incidence and mortality rates, then
ALL would be at the top of the list, and JMML would be near
the bottom. However, if adequacy of current therapy and avail-
ability of engineered models of scientific interest is considered,
then tumor types such as JMML, for which current therapy is
relatively ineffective and for which there are transgenic models
suitable for testing targeted agents, would be near the top of the
list. In making the initial selection of tumor types to study in a
preclinical testing program, it may be preferable to focus on a
limited number of tumor types. Once the preclinical testing
program’s ability to efficiently and expeditiously test new
agents is established with the initial panel of tumors, then
expansion to other tumor types could be considered.
In Vitro Model Systems. Preclinical testing programs
have historically included an in vitro testing component. In
comparison with in vivo testing, in vitro testing is less expensive
and less time-consuming. Thus, an in vitro testing panel could
potentially allow more tumor cell lines to be tested per tumor
type and could allow additional agents to be tested. Further-
more, the initial testing of combinations of agents can be con-
ducted on a cost-effective basis in vitro, whereas testing multi-
ple drug combinations in animal models is difficult. It is
important to perform in vitro testing using clinically relevant
drug concentrations and schedules.
In Vivo Model Systems. For in vivo tumor model sys-
tems, once the tumor types for initial inclusion in a preclinical
testing program are identified, decisions need to be made about
the number of models and the specific models that should be
studied for each tumor type. The selection of tumor models will
depend to some extent on the type of agent to be tested. For
example, an immune modulating agent would require testing in
immunocompetent animals and would not be testable in SCID
mice. Ideally, however, the tumor models selected should be
robust enough to be suitable for studying multiple classes of
agents. Another consideration is whether models should be
Table 3 Mouse genetic models of childhood cancers
Tumor type Comments concerning mouse model
B-cell lymphomas Mice transgenic for the c-myc gene driven by either the IgH enhancer (Emu-myc) (72, 73) or regulatory elements
of the Ig locus develop B-cell lymphomas. The Emu-myc transgenic lymphoma model has been used to
genetically analyze chemotherapy resistance, with the identification of INK4a/ARF and p53 mutations and Bcl-
2 expression as factors associated with resistance (74–76).
CNS
a, gliomas Mice engineered to express oncogenic V(12)Ha-ras using the glial fibrillary acidic protein (GFAP) promoter
uniformly developed malignant astrocytomas (77). Specific strains of mice harboring null Nf1 in and p53
alleles in cis frequently develop high-grade gliomas (78). Astrocytomas develop at low frequency in mice
heterozygous for ARF (79) and in transgenic mice expressing the v-src kinase under control of the glial
fibrillary acidic protein (GFAP) gene regulatory elements (80).
CNS, medulloblastoma Mice heterozygous for Ptch have increased propensity for developing medulloblastoma (10% develop
medulloblastoma by 9–10 months) (81–83). Development of tumors requires Igf-2 (83) and is accelerated by
loss of p53 (84). Medulloblastoma also develops in transgenic mice containing the JC virus early promoter and
T-antigen gene (85, 86).
Leukemia, MLL Mice heterozygous for the MLL-AF9 fusion protein develop acute leukemia (primarily AML), with a median time
to leukemia of approximately 5 months (87).
Leukemia, Bcr-Abl p190 Mice engineered to express Bcr-Abl p190 consistently develop pre-B-cell leukemia (88, 89). This model has been
used to test the activity of a farnesyl transferase inhibitor (90) and to demonstrate the role of the adapter
protein Crkl in leukemia development (91).
Leukemia, AML1-ETO Mice engineered to inducibly express AML1-ETO (92) or to express AML1-ETO in myeloid precursor cells (93)
do not develop leukemia. However, mutagen treatment of AML1-ETO transgenic mice produces AML (93),
which is not observed in control mice treated with mutagen.
Leukemia, PML-RAR Mice engineered to express the PML-RAR fusion protein in myeloid-promyelocytic precursor cells show
myeloproliferation in the first year of life with subsequent development of leukemia in some animals (94).
Leukemia cells isolated from transgenic mice and transplanted into nude mice were used to evaluate the
activity of retinoic acid and arsenic trioxide (95). Transgenic mice expressing PML-RAR have been used to
demonstrate that Bcl-2 can cooperate with the fusion protein in APL development (96) and that that the PML
protein acts as a tumor suppressor (97).
Leukemia, JMML See description in text (33–36).
Leukemia, T-cell ALL/
lymphoma
Mice with ectopic expression of Tal-1/Scl in lymphoid tissues can develop T-cell ALL late in life with
incomplete penetrance (98, 99). Leukemogenesis is accelerated by transgenic coexpression of casein kinase Ii
(99, 100) and by expression of LMO1 (101) or LMO2 (102). T-cell lymphoid malignancies also develop at
high frequency in E2A-deficient mice (103, 104).
Neuroblastoma See description in text (37–39).
Rhabdomyosarcoma Mice heterozygous for Ptch have increased propensity for developing rhabdomyosarcoma (10% of animals at
weeks 6–13) (82). Development of tumors requires Igf-2 (82) and is accelerated by loss of p53 (84).
Rhabdoid tumor A small percentage (10–30%) of mice heterozygous for mutant Ini1/Snf5 develop malignant rhabdoid tumors
(105–107). Tumor location is strain-dependent, with tumors primarily arising in the soft tissue of the face in
some strains (106) and with CNS tumors being more common in other strains (107).
Soft tissue sarcoma (non-
rhabdomyosarcoma)
Mice that carry linked germ-line mutations in Nf1 and p53 develop soft tissue sarcomas at high frequency,
including malignant peripheral nerve sheath tumors, malignant Triton tumors, and rhabdomyosarcoma (108,
109).
a CNS, central nervous system; AML, acute myelogenous leukemia; RAR, retinoic acid receptor.
3650 Preclinical Testing Using Childhood Cancer Modelsbased on tumors from diagnosis or on recurrent tumors. A
potential benefit for studying tumors from relapse is that these
tumors have clinically relevant mechanisms of drug resistance.
Testing using drug-resistant tumors may select for agents that
are active against tumors incurable with current therapy. Agents
identified as active in relapsed/recurrent tumor models may
better predict activity in conventional Phase II studies, whereas
models based on tumors at diagnosis may be more applicable to
predicting activity in Phase II window studies. Selecting the
number of models for each tumor type represents a compromise
between the ideal of studying a multitude of models for each
tumor type and the resource constraints that limit the number of
models that can be studied. This practical limit is probably
between 5–10 tumor models for each tumor diagnosis. The
number of models studied for each tumor type should reflect the
diversity of biological subtypes for the tumor type (e.g., embry-
onal and alveolar rhabdomyosarcoma and the various molecular
subtypes of ALL).
Characteristics of transgenic models suitable for inclu-
sion in a preclinical testing program include: (a) uniform
tumor development among independent transgenic lines; (b)
high penetrance; (c) early initiation and time to progression;
and (d) ability to be bred in large numbers. Transgenic animal
models may not be optimal for testing against all agents
because many of these models are resource-intensive when
used for testing. For transgenic models that are resource-
intensive, testing might be restricted to agents shown to be
active in xenografts of the same tumor type and to agents that
target biochemical pathways that are deregulated as a result
of the engineered genetic lesion(s) of the model. For exam-
ple, the JMML model described above may be useful for
testing agents that target constitutively active Ras, but not
other molecularly targeted therapeutics. One concern about
the applicability of transgenic models is that to have high
penetrance and early initiation, some transgenic models are
engineered to have two or more specific genetic hits in
relatively large numbers of cells. It is reasonable to question
how accurately models of this type recapitulate the patho-
genesis of human cancer. Also, transgenic models likely
reflect more the status of the human cancer at diagnosis (i.e.,
before treatment) than the status at the time of disease recur-
rence (i.e., after exposure to cytotoxic therapy). Also, the
issues related to the importance of pharmacokinetics in in-
terpreting testing results for xenograft models (see below)
apply to transgenic models.
A potential approach that has not been exploited exten-
sively involves combining traditional xenograft and transgenic
strategies. That is, cancers from genetically engineered mice or
cell lines derived from these tumors might be injected into
syngeneic immunocompetent recipients to increase the effi-
ciency of drug testing in vivo.
Once a set of candidate tumor models is selected, there
may be value in testing these models against conventional
agents with a known clinical response rate to characterize the
operating characteristics of each tumor model. This would
serve to demonstrate that benchmark agents are active in
appropriate tumor models and would enhance confidence in
the preclinical testing program. It will also be important to
have a periodic assessment of the screen in successfully
identifying effective new drugs. Benchmarks for success
should be identified prospectively, and analytic methods for
determining whether these benchmarks have been met should
be developed.
Proposed Approach
A possible design for a preclinical testing program is
presented in Fig. 1. The design anticipates that many of the
Fig. 1 Diagram of proposed pediatric test-
ing program (see the text for description).
3651 Clinical Cancer Researchagents available for testing will have known molecular targets
and that relevant transgenic models will exist for some of these
targeted agents. The design additionally recognizes that even
when an agent has a putative cellular target, there may be other
cell signaling pathways affected by the agent that may have
relevance to the therapy of childhood cancers [e.g., CEP-701
inhibits both Trk receptor tyrosine kinase activity and Flt3 (40,
41), and STI571 inhibits Bcr-Abl, c-Kit, and platelet-derived
growth factor receptor (42–44)].
For agents with general cytotoxic activity for which a
molecular target is not defined, the agent would initially be
tested at its MTD against the entire xenograft panel. For tumor
types in which responses were observed, a full dose-response
curve would be developed, and the agent would also be studied
in orthotopic or transgenic models of these tumor types when
they are available. This sequential design would minimize the
resources required to study drugs by avoiding complete dose-
response studies for agents with little or no activity in tumor
models.
For those agents with defined molecular targets, testing
could be performed at doses below the MTD if there were
convincing data documenting significant target modulation at
lower doses. Even for agents with known molecular targets,
there may be an advantage to performing the initial testing at the
MTD because antitumor activity associated with modulation of
the agent’s known target would likely be detected by testing at
the highest dose level tolerated, and activity associated with
previously unrecognized targets may be recognized. Regardless
of the dose used for the initial testing, if activity was observed,
a full dose-response study would be performed to relate antitu-
mor response to target inhibition. If the target of an agent was
one for which there was a murine genetic model with suitable
characteristics for preclinical testing, evaluation against this
model would occur in the first tier of testing. If activity was
observed in the first tier of testing for specific tumor types, then
the agent would also be studied in available orthotopic models
for these tumors.
The role of in vitro testing is not specified in Fig. 1. For
those tumor types with well-characterized cell lines, in vitro
testing could occur in parallel with in vivo testing. For those
agents showing activity in one or more xenograft or transgenic
models, in vitro testing could be especially useful in identifying
combinations including the active agent that warrant further
preclinical testing.
The infrastructure of a preclinical testing program would
include a steering committee responsible for the overall direc-
tion and activities of the consortium, the institutions performing
the testing for specific tumor types, and core resources for
biostatistical, pharmacokinetic, and correlative study support.
The institutions participating in the testing program would need
to have the animal care infrastructure to support the requisite
tumor model systems. They would need to maintain a cell line
bank and/or animal tumor models ready for testing when re-
quired. Each institution performing testing would need to meet
quality control guidelines, report data in a timely manner, share
models and data as necessary, and abide by terms of negotiated
material transfer agreements. Institutions would standardize
treatment protocols to the extent possible across the tumor types
being tested.
Essential Core Functions for a Preclinical
Testing Program
Three of the essential core functions for a preclinical test-
ing program are presented below.
Pharmacology Core. Pharmacokinetic data are essential
for interpreting the activity observed in preclinical models. Mice
may tolerate much higher systemic exposures of some drugs
than humans (e.g., DMP0840, 15–20 higher; carzelesin, 80
higher; and sulofenur, 8 higher) and may tolerate lower sys-
temic exposures of other drugs (e.g., etoposide).
3 An example of
the importance of pharmacokinetic data in interpreting the likely
clinical antitumor activity of “active” agents identified in animal
models is that of 9-aminocamptothecin and irinotecan (the for-
mer is an agent with disappointing clinical activity, whereas the
latter has substantial activity against a range of tumor types).
Comparison of the pharmacokinetic behavior of 9-aminocamp-
tothecin and irinotecan in mice and humans indicated that
the systemic exposures associated with antitumor activity in
mice were achievable in man for irinotecan (18), but not for
9-aminocamptothecin (45). Thalidomide is another example of
the importance of identifying systemic exposure to active me-
tabolites because the active metabolite of thalidomide produced
in man is not produced in mice (46).
A preclinical testing program would need a central re-
source to generate pharmacokinetic data. Such a central resource
could be at a single institution or, alternatively, could be a
“pharmacology committee” representing researchers at a several
institutions who would support the performance of pharmaco-
kinetic analyses as needed by the consortium. To minimize the
pharmacokinetic studies that need to be performed for each
agent tested, it would be advantageous for the preclinical testing
program to standardize its testing schema to a limited number of
animal strains.
Correlative Science Core. The ability to perform correl-
ative tumor biology studies in the preclinical setting will be
increasingly important as agents targeting specific signal trans-
duction pathways are evaluated. Correlative studies may estab-
lish whether molecularly targeted agents have achieved target
inhibition under test conditions (e.g., Ref. 47). Results from
these studies will be important in understanding a targeted
agent’s activity or lack of activity (i.e., illustrating an associa-
tion between pathway modulation and antitumor activity) and
may serve as a basis for establishing doses of targeted agents for
use in combination studies (i.e., selecting doses that modulate
target, even though these doses may not have antitumor activity
as a single agent). Proteomic and gene expression profiling of
tumor models could be used to characterize the presence and
activation status of specific cell signaling pathways, to compare
gene expression in preclinical model specimens with specimens
from patients, and to study changes in pathway activation status
and gene expression after drug treatment (e.g., Ref. 48). Assays
developed for use in the preclinical setting may also prove
applicable in evaluating target modulation in the clinical setting,
using either tumor tissue or a surrogate normal tissue.
3 P. J. Houghton, unpublished observations.
3652 Preclinical Testing Using Childhood Cancer ModelsBiostatistical Core. A preclinical testing program would
need biostatistical support to design and analyze its experiments.
Design and analytic methods for testing new agents using xe-
nograft models are established and are generally based on com-
parisons of either response rate or tumor volume in control
animals and animals receiving the tested agent. Five to 10
animals are used for each dose of the tested agent. Methods for
using transgenic animals for testing experimental agents are less
well developed. Specifically, the challenge of using time from
symptom development to death as an end point needs to be
addressed. For example, to detect a 2-fold difference in this time
between control and experimental animals with standard statis-
tical parameters (90% power and 0.05) would require 45
events/group.
Obstacles to Implementation of a Pediatric
Preclinical Testing Program
Multiple challenges require resolution before a pediatric
preclinical testing program becomes a reality. There are scien-
tific issues, such as the most appropriate tumor models (be they
in vitro, xenograft, or transgenic) for inclusion in a testing
program and the most efficient strategies for testing different
classes of new agents. Resource issues must be addressed be-
cause establishment of a testing program will require a substan-
tial initial and ongoing investment. Overcoming the perception
that preclinical models have inherently poor predictive value in
identifying disease-specific activity for new agents (49) must be
addressed by validating models used in the program. Perhaps
most importantly, a preclinical testing program will need con-
sistent and ongoing support from pharmaceutical companies, as
demonstrated by the timely provision of agents for systematic
preclinical testing.
Addressing intellectual property right issues and other is-
sues related to collaborations with pharmaceutical sponsors
(e.g., data rights and confidentiality, publications, timely access
to data, and control of experimental design) will be critical to the
ultimate success of a pediatric preclinical testing program. The
NCI has established collaborations with a number of sponsors
for clinical development of investigational agents, and the so-
lutions developed in the clinical context may be applicable in
some instances to preclinical collaborations. With regard to data
rights, the clinical collaborative agreements between the NCI
and pharmaceutical collaborators stipulate that clinical trial pri-
mary data regarding proprietary compounds generated in NCI-
sponsored clinical trials are made available exclusively to NCI,
the Food and Drug Administration, and the pharmaceutical
collaborator. With regard to publications, pharmaceutical col-
laborators are given 30 days to review manuscripts before
submission to assure that no collaborator confidential/proprie-
tary information is released. Collaborators may request an ad-
ditional 30-day delay in publication to allow time for patent
filing. With regard to patent rights, an issue for pharmaceutical
collaborators is their access to inventions of federally funded
researchers. Federal legislation (Bayh-Dole) prevents academic
institutions from assigning intellectual property rights to another
party except under narrowly specified conditions. The intellec-
tual property option offers the rights of first negotiation to the
pharmaceutical collaborator that supplied the investigational
agent when there is an invention related to the agent as a result
of federally funded research. If federal funds support some part
of the preclinical testing consortium, then a similar option may
be appropriate for the consortium to use. The Cancer Therapy
Evaluation Program is introducing language into agreements
with pharmaceutical sponsors for companies to provide agents
for pediatric preclinical testing in accordance with the overall
development objectives of the drug. For agents being developed
with this stipulation, the agent is distributed under a material
transfer agreement with intellectual property and data rights
provisions similar to those that govern clinical trials.
Concluding Remarks
Meeting participants considered that the scientific oppor-
tunities and clinical need discussed at the meeting provide a
strong rationale for establishing a pediatric preclinical testing
program to prioritize new agents for evaluation in children with
cancer. There is reason to be optimistic that current tumor model
systems may have tumor-specific predictive value. Among the
recent advances that support this optimism are the increased
understanding of the importance of comparisons of systemic
drug exposures in mouse models and man (18, 45, 50), the
increased availability of pediatric cell lines and xenograft tumor
models that have undergone molecular characterization, and the
increasing availability of mouse genetic models for many cancer
types. Meeting participants recognized, however, that validation
of the predictive value of preclinical models is essential and that
appropriate analytic methods will be needed to define the ability
of specific preclinical testing methods to predict clinical activity
for new agents in children.
The initial framework for the successful establishment of a
pediatric preclinical testing program has now been outlined.
Moving forward with such a program will require ongoing
commitment from academia, the pharmaceutical industry, the
Children’s Oncology Group, the NCI, and the Food and Drug
Administration. Acceptance by pharmaceutical companies of
the concept of early access for pediatric preclinical testing to
agents under clinical development will be a major factor deter-
mining the success or failure of a pediatric testing program.
Because one of the purposes of publishing the meeting summary
is to obtain feedback from academic investigators and pharma-
ceutical companies concerning the feasibility and utility of a
preclinical testing program, persons with interest in such a
program or with suggestions regarding how it should be devel-
oped are invited to contact the authors.
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